REGENXBIO RGX-202 Gene Therapy DMD 2024 ASGCT

REGENXBIO presented interim clinical data for RGX-202, an investigational gene therapy designed to treat Duchenne Muscular Dystrophy, at the American Society of Gene & Cell Therapy conference in May 2024. The therapy features a novel microdystrophin transgene engineered to encode key functional domains of naturally occurring dystrophin to prevent muscle degeneration.